Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / PSTX - Poseida Therapeutics inks license pact with TScan Therapeutics for COVID-19 therapies

PSTX - Poseida Therapeutics inks license pact with TScan Therapeutics for COVID-19 therapies

Poseida Therapeutics Inc.
Poseida Therapeutics ([[PSTX]] -0.1%) and TScan Therapeutics have entered into a research collaboration and license agreement to explore development of TCR-T cell therapies for the treatment of COVID-19.Poseida's allogeneic T cell platform will be used in combination with TScan's immunodominant epitopes and TCR sequences for the development and commercialization of allogeneic TCR-T cell therapies.Detailed financial terms of the collaboration were not disclosed.

For further details see:

Poseida Therapeutics inks license pact with TScan Therapeutics for COVID-19 therapies
Stock Information
Company Name: Poseida Therapeutics Inc.
Stock Symbol: PSTX
Market: NASDAQ
Website: poseida.com
Menu
PSTX PSTX Quote PSTX Short PSTX News PSTX Articles PSTX Message Board
Get PSTX Alerts

News, Short Squeeze, Breakout and More Instantly...